BREAST CANCER DETECTION TOOL CITED IN RECORD SPIKE OF EARLY DIAGNOSES
A radical advancement in oncology, a non-invasive blood test for breast cancer, is credited with a record 40 percent spike in early-stage diagnoses this fiscal quarter. According to a report released Monday by the Global Oncology Consortium, the new liquid biopsy technology has identified malignancy in patients an average of 28 months earlier than traditional mammography. Researchers from the consortium confirm the tool uses a proprietary algorithm to detect circulating tumor DNA, offering a specificity rate of 97.8 percent. The findings have prompted a call for international health regulators to expedite approval protocols for the screening method. HOWEVER, CRITICS WARN AGAINST RELIANCE ON A SINGLE TESTING PROTOCOL. CLINICIANS ARE ADVISED TO MAINTAIN STANDARD SCREENING MEASURES ALONGSIDE BLOOD-BASED ASSAYS.